9 / 10
Page 29
Notes:
allied
academies
Biol Med Case Rep 2017 | Volume 1 Issue 2
November 06-07, 2017 | New Orleans, USA
Nanomedicine & Healthcare
Global Meet on
NanoBindi: A clinical-outcome focused, patient-centric precision therapeutic development platform
Arkesh Mehta
OncoBindi Therapeutics, USA
A
technology-driven clinical outcome focused, patient-
centric precision therapeutic development platform
is operationally efficient and enables rapid, parallel
development of multiple products in the portfolio without
additional cost burden. Functional fabric encapsulated drugs
(single or combination), where clinical function interfaces
are integrated in the functional fabric architecture. The
preconfigured clinical function interfaces enable dynamic
integration of active targeting, increased availability at the
cancer cell, protection from host defense and on demand
controlled release for the optimal efficacy of the drug
regimen. The smart dynamically transformative, clinical-
outcome focused platform for the development of precision
therapeutics has a small foot-print, is globally scalable and
regulatory agency compliant. In this way, the platform allows
biopharmaceutical companies to develop a sustainable
product portfolio in a collaborative ecosystem.
Speaker Biography
Arkesh Mehta is a lifelong Entrepreneur with experience up and down the
biopharmaceutical spectrum, since his first startup more than 15 years ago. He has
co-founded and/or served as CEO or Executive Chairman for a set of leading-edge
biotechnology, molecular diagnostics and healthcare IT companies. These companies
had successful exits including BPI technologies, AT-GC BioPharm, Avanti NanoSciences
and CBTEK. He is an Advisor and Board Member of several bio and healthcare startups.
He has organized, Chaired and participated in number of international panels, including
organizing the First NASDAQ panel on Bio-IT. He is a Member of Trustees for Sushita
Group, a non-profit that fosters entrepreneurship.
e:
amehta@oncobindi.com